RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Tarun Mandal to Antineoplastic Agents

This is a "connection" page, showing publications Tarun Mandal has written about Antineoplastic Agents.
Connection Strength

0.684
  1. Graves RA, Ledet GA, Glotser EY, Mitchner DM, Bostanian LA, Mandal TK. Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide. Eur J Pharm Sci. 2015 Aug 30; 76:1-9.
    View in: PubMed
    Score: 0.301
  2. Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat Drug Deliv Formul. 2007; 1(1):37-51.
    View in: PubMed
    Score: 0.169
  3. Powell D, Chandra S, Dodson K, Shaheen F, Wiltz K, Ireland S, Syed M, Dash S, Wiese T, Mandal T, Kundu A. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Eur J Pharm Biopharm. 2017 May; 114:108-118.
    View in: PubMed
    Score: 0.085
  4. Ledet GA, Graves RA, Glotser EY, Mandal TK, Bostanian LA. Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles. Int J Pharm. 2015 Feb 20; 479(2):329-37.
    View in: PubMed
    Score: 0.073
  5. Bhattacharjee PS, Huq TS, Mandal TK, Graves RA, Muniruzzaman S, Clement C, McFerrin HE, Hill JM. A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. PLoS One. 2011 Jan 06; 6(1):e15905.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support